Tango Therapeutics, Inc. (TNGX)

Market Cap	780.64M
Revenue (ttm)	36.53M
Net Income (ttm)	-101.74M
Shares Out	106.72M
EPS (ttm)	-1.08
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	14,792
Open	7.30
Previous Close	7.37
Day's Range	7.27 - 7.32
52-Week Range	2.47 - 13.03
Beta	0.84
Analysts	Strong Buy
Price Target	17.25 (+137.28%)
Earnings Date	May 7, 2024

About TNGX

Tango Therapeutics, Inc., a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions. The company develops TNG462, an oral small molecule methylthioadenosine-cooperative inhibitor for the treatment for cancers with methylthioadenosine phosphorylase deletions; TNG260, a co-repressor of repressor element-1 silencin...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2014
• Employees: 140
• Stock Exchange: NASDAQ
• Ticker Symbol: TNGX

Financial Performance

In 2023, TNGX's revenue was $36.53 million, an increase of 46.93% compared to the previous year's $24.86 million. Losses were -$101.74 million, -5.95% less than in 2022.

Analyst Forecast

According to 5 analysts, the average rating for TNGX stock is "Strong Buy." The 12-month stock price forecast is $17.25, which is an increase of 137.28% from the latest price.

Price Target

$17.25

(137.28% upside)

Analyst Consensus: Strong Buy